Document Detail

Fluoropyrimidine-associated cardiotoxicity: revisited.
MedLine Citation:
PMID:  19309247     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The syndrome of 5-fluorouracil (5-FU)-associated cardiotoxicity remains poorly defined. PATIENTS AND METHODS: We performed a literature review (1969 - 2007) and compiled data derived from 377 evaluable cases out of 448 reported cases. RESULTS: Patient age ranged from 14 to 86 years. Of the patients 65% were 55 years old and the male:female ratio was 1.5:1. The most commonly treated tumors were gastrointestinal (60%), head and neck (22%) and breast (4%). Of the patients 14% had a history of heart disease whereas cardiac risk factors were found in 37%. Mode of administration included: continuous infusion (72%); bolus (22.5%); intermediate infusion (3%); oral (2%); and intraperitoneal (1 patient). The dosages of 5-FU used were < 750 mg/m(2)/day (36%), 751 - 999 (16%), 1,000 (26%), 1,001 - 1,499 (4%) and 1,500 (16%). Of the patients 54% received 5-FU in combination with other chemotherapeutic agents (cisplatin 44%) whereas 51% received 5-FU alone or with leucovorin. Only 4% patients had undergone previous or concomitant radiation therapy to the mediastinum. Of cardiac incidents that happened 69% were seen during or within 72 h of the first cycle of 5-FU. Angina occurred in 45% of patients whereas myocardial infarction was seen in 22%, arrhythmias in 23, acute pulmonary edema in 5, cardiac arrest and pericarditis in 1.4 and heart failure in 2. Electro-cardiographic evidence of ischemia or ST-T changes were recorded in 69% of patients, but abnormal cardiac enzymes were found in only 12%. The cardiac symptoms were reproducible in 47%, including in one patient subsequently treated with 5-FU p.o. Symptoms were also elicited when the same patients were treated with lower doses or different schedules. Of the patients 68% responded to conservative anti-anginal therapy, although prophylactic coronary vasodilators had limited efficacy. Overall, 8% of patients showing cardiotoxicity on 5-FU administration died. Furthermore, 13% reexposed to 5-FU died. CONCLUSIONS: Our review suggests that 5-FU cardiotoxicity is an infrequent but real phenomenon that is independent of dose and may be related to a continuous infusion schedule. The presence of cardiac risk factors is not predictive. Patients should be observed closely and 5-FU administration discontinued if cardiac symptoms develop. A rechallenge with 5-FU should be reserved only for those patients in whom there is no reasonable alternative therapy and should be performed in the setting of aggressive prophylaxis and close monitoring.
M Wasif Saif; Manasi M Shah; Anuj R Shah
Related Documents :
10759487 - Propofol-associated rhabdomyolysis with cardiac involvement in adults: chemical and ana...
2209037 - Hemodynamic and metabolic effects of dobutamine in 18 patients after open heart surgery.
8176017 - Severe adverse cardiovascular effects of pulse steroid therapy: is continuous cardiac m...
19309247 - Fluoropyrimidine-associated cardiotoxicity: revisited.
3486017 - The release of interleukin-2 (il-2) and colony stimulating activity (csa) in aplastic a...
23999527 - Neuropsychiatric disease relevance of circulating anti-nmda receptor autoantibodies dep...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on drug safety     Volume:  8     ISSN:  1744-764X     ISO Abbreviation:  Expert Opin Drug Saf     Publication Date:  2009 Mar 
Date Detail:
Created Date:  2009-03-24     Completed Date:  2009-06-15     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101163027     Medline TA:  Expert Opin Drug Saf     Country:  England    
Other Details:
Languages:  eng     Pagination:  191-202     Citation Subset:  IM    
Yale University School of Medicine, FMP 116, CT 06520, New Haven, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antimetabolites, Antineoplastic / administration & dosage,  adverse effects*,  therapeutic use
Antineoplastic Combined Chemotherapy Protocols / administration & dosage,  adverse effects,  therapeutic use
Calcium Channel Blockers / therapeutic use
Cisplatin / administration & dosage,  therapeutic use
Dose-Response Relationship, Drug
Drug Administration Routes
Drug Administration Schedule
Fluorouracil / administration & dosage,  adverse effects*,  therapeutic use
Heart Diseases / chemically induced*,  drug therapy
Leucovorin / administration & dosage,  therapeutic use
Neoplasms / drug therapy
Risk Factors
Vasodilator Agents / therapeutic use
Reg. No./Substance:
0/Antimetabolites, Antineoplastic; 0/Calcium Channel Blockers; 0/Vasodilator Agents; 15663-27-1/Cisplatin; 51-21-8/Fluorouracil; 58-05-9/Leucovorin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Recognition and management of drug-induced cytopenias: the example of idiosyncratic drug-induced thr...
Next Document:  The safety of plasma-derived von Willebrand/factor VIII concentrates in the management of inherited ...